Antileishmanial Activities of ( Z )-2-(Nitroimidazolylmethylene)-3( 2H )-Benzofuranones: Synthesis, In Vitro Assessment, and Bioactivation by NTR 1 and 2-Reference-Cited by-同舟云学术

Antileishmanial Activities of ( Z )-2-(Nitroimidazolylmethylene)-3( 2H )-Benzofuranones: Synthesis, In Vitro Assessment, and Bioactivation by NTR 1 and 2

Published:2022-11-15 Issue:11 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Navidpour Latifeh¹^ORCID,Lima Marta Lopes²,Milne Rachel²,Wyllie Susan²^ORCID,Hadj-esfandiari Narges¹,Choudhary Muhammad Iqbal³,Khan Samreen³,Yousuf Sammer³

Affiliation:

1. Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

2. Division of Biological Chemistry and Drug Discovery, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dundee, United Kingdom

3. H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan

Abstract

The antileishmanial activity of a series of ( Z )-2-(heteroarylmethylene)-3(2 H )-benzofuranone derivatives, possessing 5-nitroimidazole or 4-nitroimidazole moieties, was investigated against Leishmania major promastigotes and some analogues exhibited prominent activities. Compounds with IC 50 values lower than 20 μM were further examined against L. donovani axenic amastigotes.

Funder

No grant was received by corresponding author

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00583-22

Reference39 articles.

1. WHO. 2022. WHO Newsroom facts sheet: leishmaniasis. WHO Geneva Switzerland. https://www.who.int/news-room/fact-sheets/detail/leishmaniasis. Retrieved 8 January 2022.

2. Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)

3. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

4. Single-dose liposomal amphotericin B: an effective treatment for visceral leishmaniasis

5. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management;Sundar S;Ther Clin Risk Manag,2007

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Privileged small molecules against neglected tropical diseases: A perspective from structure activity relationships;European Journal of Medicinal Chemistry;2024-05

2. Using 5-Nitroimidazole Derivatives against Neglected Tropical Protozoan Diseases: Systematic Review;Future Pharmacology;2024-03-05

3. Synthetic product-based approach toward potential antileishmanial drug development;European Journal of Medicinal Chemistry;2024-01